Insomnia: Help me make it though the night...



Adil Virani, BSc (Pharm), Pharm D, FCSHP Associate Professor Faculty of Pharmaceutical Sciences, UBC Director, Pharmacy Services FHA, VCH-PHC, PHSA

Learning Objectives

- List 4 potential causes of chronic insomnia
- · List 4 drugs that can worsen or cause insomnia
- Be familiar with 'proper' sleep hygiene techniques
- · List the goals of therapy for insomnia
- Describe the short and long term benefits and risks associated with benzodiazepines
- Be familiar with the benefits and risks associated with the use of zopiclone and other medications used for treating chronic insomnia

Case 1. Ms. Jitters



- ID: 31 year old female with difficulty falling asleep (takes over 60 min) for the last month. She complains of daytime fatigue and takes naps
- PMHx
 - Generalized Anxiety Disorder x 2 years
 - Asthma x 15 yrs
- Meds: Takes fluoxetine 40 mg daily x 1 year which is helpful for reducing GAD symptoms by about 60%
- Salbutamol and betamethasone inhalers helpful in controlling asthma

How would you treat Ms. Jitters?

Case 2: Mr. Ian Somnia

- ID: 63 year old with fatigue, difficulty sleeping, poor concentration for 6 weeks
- HPI: otherwise healthy, no sleep apnea, no psychiatric conditions, etc.
- Social: occasional ethanol and caffeine; married; retired engineer
- Medications: occasional ibuprofen for pain, nicotine 14 mg patch (been on a patch x 7 wks)
- · Physical exam and labs unremarkable

How would you treat lan?

What is Insomnia?

- Difficulty falling asleep, maintaining sleep, or not feeling rested in spite of sufficient opportunity to sleep
- · Most common sleep complaint
- Common reason to seek advise from a health care professional
- · Can be transient or persistent

DSM IV Diagnostic Criteria for Primary Insomnia

- Difficulty initiating or maintaining sleep, or having nonrestorative sleep for at least a month
- Causes distress or impairment in social, occupational or other important areas of functioning
- Not related to medical disorder or other sleep disorder.
- · Not the result of substances

Classification of Insomnia

Primary:

Psychophysiological

Secondary:

Psychiatric, Medical, Substance Use

Categories

Transient Short-term Long-term

2-3 days
< 3 weeks
> 3 weeks

Goals of Therapy

- 1) Promote sound and restorative sleep
- 2) Minimize external (stress, noise, environment) and internal (anxiety, mood, pain) factors
- Reduce daytime impairment (fatigue, poor concentration) and complications of lack of sleep
- 4) Improve the effectiveness of behavioural interventions in managing patients with primary, chronic insomnia

Treatment of Insomnia

Step 1: Get a good history, consider a sleep diary, look for potential underlying causes

Step 2: Nonpharmacological therapy

Step 3: Pharmacological options



What information do you need for both these cases?

Sleep History


- Time dat
 - Napping, bed time, lights, how long to fall asleep, how many times awoken, longest awake period, time out of bed, hours of sleep
- Questions about the sleep period
 - Physical symptoms preventing sleep (pain), mental or emotional symptoms (worry, anxiety), what awakens during the night (snoring, gasping for air, nightmares), symptoms when you wake up (headache, confusion, sleepiness)
- Questions for the patient's bed partner
 - Snoring, gasping, breathing; leg twitching, jerking, kicking; alcohol, nicotine, caffeine, other drugs; change in mood or emotional state

Sleep History Questionnaire		SLEEP PATTERN Circle the days of the week you work:				
Sazae: Dete:		Monday Tuesday Wednesday Thursday Friday	Sanirda	y Su	nday	
Sirthdate: Age: Occupation:	2. (ON WORKDAYS				
Sex: Height: Weight: Weight Last Year:		What time do you go to bed:				
Referring Doctor: Family Doctor:	1	What time do you get our of bed:				
Describe your sleep problem:	3. (ON WEEKENDS & HOLIDAYS				
		What time do you go to bed:				
What results do you expect:	1	What time do you get out of bed:				
	4. 1	How long does it take for you to fall asleep?				
A. MEDICATION SURVEY	5. I	How many times a night do you awaken?				
Please list all PRESCRIPTION and NON-PRESCRIPTION medications you're curr		How long do the averkenings last?				
MEDICATION REASON TAKEN	1	List any symptoms associated with the awakenings:				
	6. 3	SLEEP THE		_	_	
		How many hours do you usually sleep? (do not include hours ment in bed make)	_			
	1	. How many hours does it take to make you feel rested?				
		. How many daytime naps do you take per week?				
	7. :	SLEEP QUALITY				
		Do you feel unrefreshed and still sleepy upon awakening?			YES	NO
ALLERGIES	1	b. How long does it take to fully awaken in the morning?				
B. PLEASE LIST ALL PAST OR PRESENT MEDICAL CONDITIONS OR SU	8. 1	n the daytime, are you chronically sleepy, fatigued or tired?			YES	NO
	9.	Grade your tendency to <u>FAIL ASLEEP</u> during the following sin Dwrould never sleep, Iwslight chance of sleeping, Iwasoderne chance of sle	nations: seping. 3	ekigk d	inuce of s	(seping)
		a. Sitting and reading	0	1	2	3
		a. Sitting and reading b. Watching TV	\rightarrow	_	-	_
		c. Sitting inactive in a public place (e.g. theater or meeting)				
		 d. As a passenger in a car for an hour without a break e. Lying down to rest in the afternoon. 	\rightarrow			\vdash
		f. Sitting and talking to someone	\rightarrow			
		g. Sirting quietly after lunch without alcohol	=			
		h. In a car, while stopped for a few minutes				1

D. SLEEP AND BREATHING Do you snore? Is your snoring broken by besitations, gasps and snorts? Are the besitations long enough to frighten your sleep py. Has your snoring driven your bed partner from the bedre	H. FAMILY HISTORY AGE Father: Mother:	МЕ	DICAL CONDITIO	
Do you awaken with a dry mouth? Do you awaken with headaches?				
INSOMPIA Do you have trouble falling or staying asleep? Do you worry about being able to fall asleep on time?		(co		
Do you feel sleepy prior to getting into bed? Does your mind race with thoughts when lying awake? Do daytime worries keep you awake at night? Does pain disturb your sleep?	List any relatives who	have sleep problems or	smore?	
Does heat, cold, hunger or thirst disturb your sleep? Is your insoumin the primary reason your life is in disart Do you rely on a sleeping medication? Do you watch TV, read, or work in bed?	I. PERSONAL HISTORY	l' (Chack any and all that app		
1. Do you frequently travel across 2 or more time zones? SLEEP DISTURBANCES Do you experience unpleasant leg sensations at bedrime lo you size to girk your legs and/or arms during sleep? Do you have swests or awaken from sleep feeling flushe los you saveleen with a bitme or acid tasse?	skipped heart beats high blood pressure epitepsy must congestion autum.	beart failure thyroid problems beardaches deviated must septum glaucome	heart attack diabetes emphyseum enlarged tomils degression/maxiety	baset moraner stoke sinusitis allergies Bipolar disorder
Do you frequently have nightmares or vivid dreams?	J. BED PARTNER QUES	TIONNAIRE (Please hr	re your bed partner check	k may and all that apply)
Do you grind your neeth or have bitten your closek durin. Have you ever vailed or indied in your sleep? Have you ever vailed or milded in your sleep? Have you ever seen or felt times from your desams of the fact that you ever seen or felt times from your desams of the fact that you ever experienced weekleses when langiting or 1. Have you ever had unusual movements or behaviors dur Describe:	Light sporing Heavy sporing Presses in breething Succeting Tooth grinding	Sleep welking Sleep talking Bod-woring Mend rocking banging A shaking fit	Leg or body twitching Leg jerking Daytime sleepiness Daytime confusion Deposition/matiety	·
PERSONAL HABITS Do you use tobacco now or have you in the poor? a. If yes, how many per day and for how many years? b. If yes, what time of day is your last use?	Provide additional detail occurs, and how offen it	il regarding any of the ab t occurs.	ove. Please describe	e the activity, the time it
Do you drink sicolo? a. If yes, how many drinks? per day / per v b. If yes, what tune of day is your last drink? How many caffeinated beverages do you drink per day? a. If yes, what tune of day is your last drink?	K. ADDITIONAL INFOR	RMATION		

Medications that can Cause or Worsen Insomnia

- · Antidepressants
 - bupropion, fluoxetine, SNRIs, MAOIs, TCAs
- · Antihypertensives
 - beta blockers, methyldopa
- Nicotine
- · Sympathomimetic Amines
 - amphetamines, methylphenidate, caffeine, cocaine, decongestants, appetite suppressants, bronchodilators (e.g.,
- Miscellaneous
 - corticosteroids, anticonvulsants (e.g., phenytoin, valproic acid), levodopa, quinidine, hormones (e.g., thyroid supplements, estrogen)



Nonpharmacological Options

- Proper sleep hygiene (see slide in handout)
- · Relaxation exercises and tapes
- · Stimulus control
- · Sleep restriction
- Sleep diary (see sample in handout)
- Increase aerobic exercise earlier in the day (~45 minutes and should induce sweating)
- Cognitive behavioural therapy for insomnia (CBTi)

		C	OMPLE	Nationa Nationa		Foundat	ion Siee		MPLET	E AT EN	D OF D	ΑY
Pill out days 1-4 below and days 5-7 on page 2	I went to bed last night at	I got out of bed this morning at:	Last night, I fell asleep in:	I woke up during the right: (Accordance of these)	When I woke up for the day, I felt: (Stet an)	Last night I slept a total of: (Read number of hum)	My sleep was disturbed by: Lat any metal, motional physical or environmental factor that offered year sings, rooking physical charming, temporature)		I exercised at least 20	Approximatel y 2-3 hours before going to bed, I consumed:	Medication(s) I took during the day: List new d restination(hydi)	About 1 he before gol to sleep, I the follow activity: (Litrathity au with TV work real)
DAY I DAY DATE	PM/AM	PM/AM	Minutes	Times	Carreshed Carreshed Carreshed Carreshed Carreshed	Hours		Morning Afternoon Withinseveral hous before going to bed Not applicable	Morning Afternoon Within several hours before going to bed Not applicable	☐ Alcohol ☐ A heavy meal ☐ Not applicable		
DAY 2 DAYDATE	PM/AM	PM/AM	Minutes	Times	Refreshed Somewhat refreshed fatigued	Hours		Morning Afternoon Withinseveral hous before going to bed Not applicable	Morning Afternoon Within several hous before going to bed Not applicable	Alcohol A heavy meal Not applicable		
DAY 3 DAY	PM/AM	PM/AM	Minutes	Ime	Refreshed Somewhat refreshed	Hours		Morning Afternoon Withinseveral hours before going to bed		☐ Alcohol ☐ A heavy meal ☐ Not		

Sleep Hygiene

- Keep a regular sleep/wake schedule 7 days a week Limit daily "in-bed" time to average sleep time prior to the sleep disturbance 2.
- Avoid sleeping in or daytime naps
- Stop offending medications/substances (caffeine, nicotine, alcohol, stimulants)
- Avoid evening stimulation
- Try a warm, 20 minute bath near bedtime
- 7. Eat regularly during the day and avoid large meals near bedtime
- Use bedroom only for sleep and intimacy not for TV or something that keeps you too alert

Pharmacological Options

- **Antihistamines**
- Benzodiazepines
- Zopiclone
 - Eszopiclone*
 - · Zaleplon*/Indiplon*
 - Zolpidem*
 - Antidepressants (e.g., trazodone, doxapin)
 - Alcohol?

- Melatonin
- · Ramelteon* (melatonin receptor agonist)
- · Chloral Hydrate
- · Antipsychotics
- · L-Tryptophan
- Herbs (valerian, chamomile)

*Not available in Canada

6 Basic Principles

- · Use lowest effective dose
- Intermittent dosing (PRN) e.g., <4/week
- Short term treatment (2-4 weeks) depending on presentation
- · Need for medication tapering if longer term
- Select and monitor medications by assessing daytime functioning and adverse effects
- · Patient plays an active role in treatment

Benzodiazepines

- Effective in promoting sleep onset and maintaining sleep
- Consider half-life and metabolites
 - Particularly for the elderly
 - Increased risk of higher cortical impairment

 Confusion and falls
 - · Reduced Phase I metabolism
 - · Reduced GFR and hepatic blood flow
 - "LOT" lorazepam, oxazepam, temazepam

Benzodiazepines

 Bind to gamma sub-unit of GABA-A receptor, resulting in an increase in GABA-A receptor activity

Improve insomnia by:

- · Reducing REM sleep
- · Decreasing sleep latency
- · Decrease nocturnal awakenings
- Tolerance develops with repeated administration

Problems with Benzodiazepines

- · Short-term
- · Long-term
- Adverse effects
- Tolerance
- Carry-over effects
- Withdrawal
- Cognition
- Rebound
- Anterograde amnesia
- Dependence

Adverse Effects of BDZs

- · Daytime drowsiness/tiredness
- · Cognitive impairment
- · Rebound insomnia (even after 2 wks)
- Anterograde amnesia
- · Incoordination and falls
- Paradoxical effects
- · Respiratory depression
- Dependence/tolerance
- · Sleep walking?

Physical Dependence vs. Abuse

- · Physical Dependence:
 - Down regulation of benzodiazepine receptor sensitivity
 - Need to continue to use a drug to relieve or avoid physical withdrawal symptoms
- Abuse
 - Recreational use
 - Continued use despite negative consequences
 - Dose escalation
 - Loss of control over use

Zopiclone

- · Acts at the benzodiazepine receptor
 - Not a benzodiazepine
- Compared to benzodiazepines, zopiclone appears to have less or no:
 - Rebound insomnia
 - Tolerance and dependence
 - Amnesic effects
 - Morning hang-over (short half life)

Zopicione Pharmacokinetics

Absorption: Elderly: 75% to 94%

• Protein binding: ~45%

· Metabolism: Extensively hepatic

• $T_{1/2}$: 5 hours; Elderly: 7 hours; Hepatic

impairment: 11.9 hours

Time to peak, serum: <2 hours; Hepatic

impairment: 3.5 hours

• Excretion: Urine (75%); feces (16%)

Zopiclone

- · Drug interactions:
 - CNS depressants
 - CYP2C9 and CYP3A4 drugs (inducers and inhibitors)
- Adverse effects: bitter taste, dry mouth, headache, somnolence
- Serious AEs: suicidal ideation, aggression, worsening of depression
- · Eszopiclone (Lunesta) available in the US

Zolpidem (Ambien or Sublinox)*

- Non-benzodiazepine, binds to the omega -1 (BZ-1) receptor subtype of the GABA-A receptor complex.
- · Rapid onset of action; sleep onset/duration
- T_{1/2}: 2.5 3 h
- 5 10 mg Sublingual (sublinox), 6.25 mg CR (Ambien) before bedtime
- Common SE: nausea, dizziness, drowsiness, rebound insomnia
- Serious SE: suicidal ideation, worsening of depression, aggressive behaviour
- Contraindications: severe hepatic impairment, respiratory insufficiency

*Not currently sold in Canada

Trazodone

- Limited data in primary insomnia (only 2 studies)
- · Lack of objective efficacy measures
- Short duration of trials (longest is 6 weeks)
- Consideration for side effects (sedation, dizziness, orthostasis, psychomotor impairment, priapism, etc.)

Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005 Apr;66(4):469-76.

Trazodone vs. zolpidem

- 14 day, placebo controlled, primary insomnia
- Subjective sleep latency and duration showed significant improvement with both trazodone and zolpidem vs. placebo
- · Effect was greater with zolpidem

Silber MH. Clinical practice. Chronic insomnia. N Engl J Med. 2005 Aug 25;353(8):803-10.

Doxepin

- · Limited data in elderly primary insomnia
- Dose = 1-3 mg!
- 12 week RCT, DB, Dox 1 mg (n = 77) or Dox 3 mg (n = 82), or placebo (n = 81)
- Outcomes: Polysomnography (PSG), patient and clinician ratings, CGI at nights 1, 29, and 85

Results:

DXP 3 mg > placebo for all measures and 1mg > placebo for some outcomes

Krystal AD et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. SLEEP 2010:33(11):1553-1561.

Antipsychotics

- · Not FDA approved for insomnia
- When used, doses are usually lower than those for treating psychosis
- Can be helpful, but associated with weight gain, increased risk for diabetes, high blood pressure, restless leg syndrome, muscle spasm or Parkinson-like symptoms
- Quetiapine and ziprasidone have been studied in clinical trials and were shown to increase total sleep time as well as sleep efficiency

Adil's Comparison of First Line Drugs in Canada for Insomnia

Drug	Night-time Dose (mg)	Half-life (hours)	Metabolites	Comments
Lorazepam	Initial 0.5 Maximum 1	10 to 20	Inactive metabolite	No "hangover" effects; may cause more rebound insomnia on withdrawal than temazepam or oxazepam; may cause amnesia with higher doses
Oxazepam	Initial 15 Maximum 30	5 to 10	Inactive metabolite	Slowly absorbed – delayed onset of action; take 60-90 minutes before retiring; no "hangover" effects
Temazepam	Initial 7.5 Maximum 30	10 to 12	Inactive metabolite	Short duration of action limits morning sedation Does not accumulate.
Triazolam	Initial 0.125 Maximum 0.25	2 to 3	Inactive metabolite	Anterograde amnesia (esp. with † dose, concomitant alcohol); other dose-related side effects (rebound insomnia, daytime anxiety) have limited its use. Absence of "hangover" effects is major advantage.
Zopiclone	Initial 3.75 Maximum 7.5	5 to 10	N-Desmethyl (has activity) N-Oxide (has weak activity)	Does not accumulate; free of cognitive effects major adverse effect is bitter/metallic taste; ma cause less rebound on withdrawal; minimal additive effects with low doses of alcohol



Drug	Dosage Form	Recommended Dosage	Indications/Specific Comments
Benzodiazepine Receptor	r Agonistic Modulator	(Schedule IV Controlled Substances)	
Non-benzodiazepines			
cyclopyrrolones eszopiclone	1, 2, 3 mg tablets	2-3 mg hs 1 mg hs in elderly or debilitated; max 2 mg 1 mg hs in severe hepatic impairment; max 2 mg	Primarily used for sleep-onset and materiance insomnia; Intermediate-acting; No short-term usage restriction
imidazopyridines zolpidem	5, 10 mg tablets	10 mg hs; max 10 mg 5 mg hs in elderly, debilitated, or hepatic impairment	Primarily used for sleep-onset insome Short-to intermediate-acting
zolpidem (controlled release)	6.25, 12.5 mg tablets	12.5 mg hs 6.25 mg hs in elderly, debilitated, or hepatic impairment	 Primarily used for sleep-onset and matenance insommia; Controlled release; swallow whole, divided, crushed or chewed
pyrazolopyrimidines zaleplon	5, 10 mg capsules	10 mg hs; max 20 mg 5 mg hs in elderly, debilitated, mild to moderate hepatic impairment, or concomitant cimetidine	Primarily used for sleep onset insom Maintenance insomnia as long as 4 ho is available for further sleep Short-acting
Benzodiszepines			
estazolam	1, 2 mg tablets	1-2 mg hs 0.5 mg hs in elderly or debilitated	♦ Short- to intermediate-acting
temazepam	7.5, 15, 30 mg capsules	15-30 mg hs 7.5 mg hs in elderly or debilitated	♦ Short- to intermediate-acting
triazolam	0.125, 0.25 mg tablets	0.25 mg hs; max 0.5 mg 0.125 mg hs in elderly or debilitated; max 0.25 mg	♦ Short-acting
flurazepam	15, 30 mg capsules	15-30 mg hs 15 mg hs in elderly or debilitated	Long-acting Risk of residual daytime drowsiness
Melatonin Receptor Ago	nists (Non-Scheduled)		
ramelteon	8 mg tablet	8 mg hs	 Primarily used for sleep-onset insom

Agents	Recommended Dose	Comments
Zopiclone	3.75-7.5 mg	Short half-life provides lower risk of morning hang-over effect Metallic after-taste most common adverse reaction
Temazepam	15-30 mg	Intermediate half-life carries a low-moderate risk of morning hang-over effect
		derate level of formal evidence. Extent of current use and bility support use as second-line agents
Agents	favorable tolera	bility support use as second-line agents
	favorable tolera	bility support use as second-line agents Comments
Agents	favorable tolera Recommended Dose	bility support use as second-line agents Comments Shorter half-life carries lower risk of morning hang-over
Agents	favorable tolera Recommended Dose	bility support use as second-line agents Comments - Shorter half-life carries lower risk of morning hang-over effect
Agents Trazodone	Recommended Dose 25-50 mg	bility support use as second-line agents Comments Shorter half-life carries lower risk of morning hang-over effect Variable Evidence Comments Vidence supporting efficacy is variable and
Agents Trazodone gents	Recommended Dose 25-50 mg Recommended Dose	bility support use as second-line agents Comments Shorter half-life carries lower risk of morning hang-over effect Variable Evidence Comments

	Usual Dose	Comments
Diphenhydramine - Benadryl® - Sleep Eze - Simply Sleep - Nytol® - Unisom®	25-50 mg hs	Potential for serious side effects arising from anticholinergic properties (especially in elderly); residual daytime sleepiness, diminished cognitive function, dry mouth, blurred vision, constipation, urinary retention, etc. These products are not intended for long term use and tolerance to sedative effects likely develops rapidly (3
Dimenhydrinate - Gravol	25-50 mg hs	days)
Doxylamine - Unisom 2	25-50 mg hs	Gravol not approved in Canada as a sleep aid

Agents	Comments
Antidepressants - mirtazapine, fluvoxamine, tricyclics	Relative lack of evidence
Amitriptyline	Relative lack of evidence and significant adverse effects (such as weight gain)
Antihistamines - chlorpheniramine	Relative lack of evidence or excessive risk of daytime sedation, psychomotor impairment and anticholinergic toxicity
Antipsychotics (Conventional or 1st-Generation) - chlorpromazine, methotrimeprazine, loxapine	Relative lack of evidence and unacceptable risk of anticholinergic and neurological toxicity
Antipsychotics (Atypical or 2nd-Generation) - risperidone, olanzapine, quetiapine	Relative lack of evidence and unacceptable cost and risk of metabolic toxicity
Benzodiazepines (Intermediate and Long- Acting) - diazepam, clonazepam, flurazepam, lorazepam, nitrazepam, alprazolam, oxazepam Benzodiazepines (Short-Acting) - triazolam	Excessive risk of daytime sedation and psychomoto impairment No longer recommended due to unacceptable risk of memory disturbances, abnormal thinking and psychotic behaviors

Selected References

- Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insominia in adults. J Clin Sleep Med. 2008 Oct 15,4(5):487-504. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2576317/pdf/jcsm.4.5.487.pdf Neubauer DN. Current and new thinking in the management of comorbid insomnia. Am J Manag Care. 2009 Feb;15 Supplis:24-32. Available from: http://www.ajmc.com/media/pdf/A228_09feb_Neubauer_S24to32.pdh

 Toward Optimized Practice Program. Guideline for adult primary insomnia. 2010 Feb. Available from: http://lopalbertadoctors.org/informed_practice/clinical_practice_guidelines/complete_%2/0set/Insomnia/insomnia_management_guideline.pdf

 Bhat A, Shaff F, El Solh AA. Pharmacotherapy of insomnia. Expert Opin Pharmacother. 2008 Feb;9(3):351-62.

 Wilson SL, Nutt DJ, Alford C, et al. British Association for Psychopharmacology.
- 3.

- 2008 Feb:9(3):351-62
 Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based freatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010 Nov;24(11):1577-691.
 National Institute for Clinical Excellence, Guidance on the use of zaleplon, zolpidem and zopiclone for the short-lerm management of insomnia 2004 Apr. Available from: http://www.nice.org.uk/nicemedia/live/11530/32845/32845.pdf
 Sullivan SS, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs. 2009 Sep:14(3):411-22.
 Passarella S, Dungo MT. Diagnosis and treatment of insomnia. Am J Health Syst Pharm. 2008 May 15:65(10):927-34.

- 9.
- 2008 May 15:65(10):927-34.
 NIH state-0-the-science conference on manifestations and management of chronic insomnia in adults. 2005 Jun. Available from: http://consensus.nih.gov/2005/insomniastatement.pdf
 Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Steen Med Rev. 2009 Aur.13(4):786-73.

QUESTIONS???